Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon

Clinical Science

Volumn 131, Issue 21, 2017, Pages 2611-2626

  Couch, Daniel G ^a   Tasker, Chris ^a   Theophilidou, Elena ^a   Lund, Jonathan N ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABIDIOL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PALMIDROL; PHOSPHOPROTEIN; STROMELYSIN; TUMOR NECROSIS FACTOR; AMIDE; ANTIINFLAMMATORY AGENT; CYTOKINE; ETHANOLAMINE DERIVATIVE; PALMITIC ACID DERIVATIVE; TNF PROTEIN, HUMAN;

ACUTE APPENDICITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CACO-2 CELL LINE; COLON TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; INTESTINE CANCER; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; ACUTE DISEASE; CHEMISTRY; COLON; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; METABOLISM;

ACUTE DISEASE; AMIDES; ANTI-INFLAMMATORY AGENTS; CACO-2 CELLS; CANNABIDIOL; COLON; CYTOKINES; ETHANOLAMINES; HUMANS; INFLAMMATORY BOWEL DISEASES; PALMITIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85032825924     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20171288     Document Type: Article

References (48)

1. van der Flier, LG and Clevers, H. (2009) Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71, 241-260
2. Kim, Y.S. and Ho, S.B. (2010) Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr. Gastroenterol. Rep. 12, 319-330
3. Coskun, M. (2014) Intestinal epithelium in inflammatory bowel disease. Front. Med. 1, 1-5
4. Peterson, L.W. and Artis, D. (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141-153
5. Lee, S.H. (2015) Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. 9100, 11-18
6. de Punder, K. and Pruimboom, L. (2015) Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front. Immunol. 6, 223
7. Okamoto, R. and Watanabe, M. (2016) Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J. Gastroenterol. 51, 11-21
8. Harrison, D.A., Welch, C.A. and Eddleston, J.M. (2006) The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit. Care 10, R42
9. Vaishnavi, C. (2013) Translocation of gut flora and its role in sepsis. Indian J. Med. Microbiol. 31, 334-342
10. Alhamoruni, A., Wright, K.L., Larvin, M. and O'Sullivan, S.E. (2012) Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br. J. Pharmacol. 165, 2598-2610
11. Alhamoruni, A., Lee, C., Wright, K.L., Larvin, M. and O'Sullivan, S.E. (2010) Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J. Pharmacol. Exp. Ther. 335, 92-102
12. Borrelli, F., Romano, B., Petrosino, S., Pagano, E., Capasso, R., Coppola, D. et al. (2015) Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br. J. Pharmacol. 172, 142-158
13. Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F. and Konikoff, F.M. (2013) Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 11, 1276.e1-1280.e1
14. Karwad, M.A., Macpherson, T., Wang, B., Theophilidou, E., Sarmad, S., Barrett, D.A. et al. (2016) Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARa. FASEB J., doi:fj.201500132
15. Parrella, E., Porrini, V., Iorio, R., Benarese, M., Lanzillotta, A., Mota, M. et al. (2016) PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia. Brain Res. 1648, 409-417, doi:10.1016/j.brainres.2016.07.014
16. Skaper, S.D., Facci, L. and Giusti, P. (2013) Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 48, 340-352
17. de Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., de Winter, B.Y., Scuderi, C. et al. (2011) Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One 6, 1-8
18. Esposito, G., Capoccia, E., Turco, F., Palumbo, I., Lu, J., Steardo, A. et al. (2014) Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-a activation. Gut Aug;63(8) 1300-1312
19. Harvey, B.S., Sia, T.C., Wattchow, D.A. and Smid, S.D. (2014) Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine 65, 236-244
20. von Ziegler, L.M., Saab, B.J. and Mansuy, I.M. (2013) A simple and fast method for tissue cryohomogenization enabling multifarious molecular extraction. J. Neurosci. Methods 216, 137-141
21. Borrelli, F. and Izzo, A.A. (2009) Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract. Res. Clin. Endocrinol. Metab. 23, 33-49
22. Jamontt, J.M., Molleman, A., Pertwee, R.G. and Parsons, M.E. (2010) The effects of delta 9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br. J. Pharmacol. 160, 712-723
23. Cuzzocrea, S., Campolo, M., Impellizzeri, D., Paterniti, I., Bruschetta, G., Cordaro, M. et al. (2014) Palmitoylethanolamide ameliorates development of colitis caused by injection of dinitrobenzene sulfonic acid in mice (840.3). FASEB J. 28, suppl 1:840.3
24. Erlejman, A.G., Jaggers, G., Fraga, C.G. and Oteiza, P.I. (2008) TNFa-induced NF-κB activation and cell oxidant production are modulated by hexameric procyanidins in Caco-2 cells. Arch. Biochem. Biophys. 476, 186-195
25. Di Marzo, V., Melck, D., Orlando, P., Bisogno, T., Zagoory, O., Bifulco, M. et al. (2001) Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358, 249-255
26. De Petrocellis, L., Davis, J.B. and Di Marzo, V. (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506, 253-256
27. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I. et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852
28. Correa, F., Hernangómez, M., Mestre, L., Loría, F., Spagnolo, A., Docagne, F. et al. (2010) Anandamide enhances IL-10 production in activated microglia by targeting CB 2 receptors: Roles of ERK1/2, JNK, and NF-κB. Glia 58, 135-147
29. Harada, A., Sekido, N., Akahoshi, T., Wada, T., Mukaida, N. and Matsushima, K. (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J. Leukoc. Biol. 56, 559-564
30. Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X.F. et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101, 311-320
31. Zhang, Z., Zheng, M., Bindas, J., Schwarzenberger, P. and Kolls, J.K. (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12, 382-388
32. Deshmane, S.L., Kremlev, S., Amini, S. and Sawaya, B.E. (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 313-326
33. Wicks, I.P. and Roberts, A.W. (2015) Targeting GM-CSF in inflammatory diseases. Nat. Rev. Rheumatol. 12, 37-48
34. Nagase, H. and Woessner, J.F. (1999) Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494
35. Jarry, A., Crémet, L., Caroff, N., Bou-Hanna, C., Mussini, J.M., Reynaud, A. et al. (2015) Subversion of human intestinal mucosa innate immunity by a Crohn's disease-associated E. coli. Mucosal Immunol. 8, 572-581
36. Nagarkatti, P., Pandey, R., Rieder, S.A., Hegde, V.L. and Nagarkatti, M. (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 1, 1333-1349
37. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R. and Vogel, Z. (2010) Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 285, 1616-1626
38. Izzo, A.A., Capasso, R., Pinto, L., Di Carlo, G., Mascolo, N. and Capasso, F. (2001) Effect of vanilloid drugs on gastrointestinal transit in mice. Br. J. Pharmacol. 132, 1411-1416
39. Capasso, R., Orlando, P., Pagano, E., Aveta, T., Buono, L., Borrelli, F. et al. (2014) Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB receptors and TRPV1 channels. Br. J. Pharmacol. 171, 4026-4037
40. Ho, W.-S.V., Barrett, D.A. and Randall, M.D. (2008) "Entourage" effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 155, 837-846
41. Capasso, R., Borrelli, F., Aviello, G., Romano, B., Scalisi, C., Capasso, F. et al. (2008) Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Pharmacol. 154, 1001-1008
42. de Filippis, D., Iuvone, T., D'amico, A., Esposito, G., Steardo, L., Herman, A.G. et al. (2008) Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol. Motil. 20, 919-927
43. Krohn, R.M., Parsons, S.A., Fichna, J., Patel, K.D., Yates, R.M., Sharkey, K.A. et al. (2016) Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. J. Inflamm. (Lond) 13, 21
44. De Petrocellis, L., Orlando, P., Moriello, A.S., Aviello, G., Stott, C., Izzo, A.A. et al. (2012) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. 204, 255-266
45. Pazos, M.R., Mohammed, N., Lafuente, H., Santos, M., Martínez-Pinilla, E., Moreno, E. et al. (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors. Neuropharmacology 71, 282-291
46. Cassol, Jr, O.J., Comim, C.M., Silva, B.R., Hermani, F.V., Constantino, L.S., Felisberto, F. et al. (2010) Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res. 1348, 128-138
47. Di Sabatino, A., Battista, N., Biancheri, P., Rapino, C., Rovedatti, L., Astarita, G. et al. (2011) The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol. 4, 574-583
48. Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M. et al. (2017) Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. Dig. Dis. Sci. 62 (6), 1615-1620, doi:10.1007/s10620-017-4540-z